$49.80 +0.83 (%) Alkermes PLC - NASDAQ

Jul. 22, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Alkermes down after drug fails

    IBD | Jan. 21, 2016 | 18:42PM EST
  2. Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes Shares Slide Following Announcement of Failed Depression Drug Trial

    Benzinga | Jan. 21, 2016 | 14:42PM EST
  3. Alkermes Hits Two-Year Low On Depression Drug Failure

    IBD | Jan. 21, 2016 | 13:02PM EST
  4. Mid-Day Market Update: US Stocks Turn Higher; Plexus Shares Gain On Strong Results

    Benzinga | Jan. 21, 2016 | 12:20PM EST
  5. Mid-Morning Market Update: Markets Drop; Verizon Profit Tops Estimates

    Benzinga | Jan. 21, 2016 | 09:55AM EST
  6. 10 Stocks Moving In Thursday's Pre-Market Session

    Benzinga | Jan. 21, 2016 | 08:19AM EST
  7. AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs

    GuruFocus | Jan. 4, 2016 | 11:59AM EST
  8. Alkermes Reports Achievement of Milestones for CNS Medicines in Proprietary Product, Pipeline Portfolio

    Benzinga | Dec. 16, 2015 | 07:09AM EST
  9. U.S.-Traded Eurozone Stocks React Mildly To ECB Vote

    IBD | Dec. 3, 2015 | 18:11PM EST
  10. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

    Benzinga | Sep. 30, 2015 | 04:37AM EST
  11. Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating

    Benzinga | Sep. 2, 2015 | 10:58AM EST
  12. Benzinga's Volume Movers

    Benzinga | Sep. 1, 2015 | 10:27AM EST
  13. Morning Market Gainers

    Benzinga | Sep. 1, 2015 | 09:44AM EST
  14. Underappreciated Leader Skips Over Equal-Weight In Double Upgrade

    Benzinga | Sep. 1, 2015 | 09:04AM EST
  15. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 1, 2015 | 08:13AM EST
  16. Benzinga's M&A Chatter for Tuesday June 16, 2015

    Benzinga | Jun. 16, 2015 | 18:04PM EST
  17. US Stock Futures Decline Ahead Of Housing Starts Report

    Benzinga | Jun. 16, 2015 | 07:22AM EST
  18. Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

    Benzinga | Jun. 16, 2015 | 07:01AM EST
  19. Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil Published in JCP

    Benzinga | Jun. 9, 2015 | 16:01PM EST
  20. US Stock Futures Edge Lower; GDP Report In Focus

    Benzinga | May. 29, 2015 | 07:47AM EST
  21. Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting of the Consortium of Multiple Sclerosis Centers

    Benzinga | May. 29, 2015 | 07:05AM EST
  22. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

    Benzinga | May. 26, 2015 | 04:15AM EST
  23. Benzinga's Top Initiations

    Benzinga | May. 21, 2015 | 09:07AM EST
  24. Barclays Initiates Alkermes With Overweight

    Benzinga | May. 21, 2015 | 08:49AM EST
  25. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga | Mar. 2, 2015 | 07:36AM EST
  26. Stocks Mostly Higher: Time Warner Clears Buy Point

    IBD | Feb. 24, 2015 | 14:53PM EST
  27. Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

    Benzinga | Jan. 14, 2015 | 14:37PM EST
  28. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

    Benzinga | Jan. 12, 2015 | 11:03AM EST
  29. Alkermes pops to 15-year high

    IBD | Jan. 7, 2015 | 18:51PM EST
  30. Alkermes Hits High On Schizophrenia Drug Results

    IBD | Jan. 7, 2015 | 12:03PM EST
  31. Morning Market Gainers

    Benzinga | Jan. 7, 2015 | 09:38AM EST
  32. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 7, 2015 | 08:10AM EST
  33. Benzinga's Volume Movers

    Benzinga | Jan. 6, 2015 | 10:45AM EST
  34. 3 Biotech ETFs Rally On Merger News

    Benzinga | Dec. 8, 2014 | 17:43PM EST
  35. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga | Nov. 11, 2014 | 04:15AM EST
  36. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  37. Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic

    Benzinga | Sep. 3, 2014 | 07:04AM EST
  38. US Stock Futures Rise Ahead Of Economic Data

    Benzinga | Aug. 25, 2014 | 07:28AM EST
  39. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For Alkermes plc

    Benzinga | Aug. 14, 2014 | 09:40AM EST
  40. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga | Apr. 30, 2014 | 07:32AM EST
  41. Alkermes' drug passes trial

    IBD | Apr. 8, 2014 | 18:54PM EST
  42. Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins

    Benzinga | Apr. 8, 2014 | 16:54PM EST
  43. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD | Apr. 8, 2014 | 16:21PM EST
  44. Mid-Afternoon Market Update: Markets Recover Slightly as Coal Shows Strength

    Benzinga | Apr. 8, 2014 | 15:46PM EST
  45. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On Lower Forecast

    Benzinga | Apr. 8, 2014 | 13:22PM EST
  46. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD | Apr. 8, 2014 | 12:12PM EST
  47. Benzinga's Volume Movers

    Benzinga | Apr. 8, 2014 | 10:55AM EST
  48. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit Outlook

    Benzinga | Apr. 8, 2014 | 10:29AM EST
  49. Morning Market Movers

    Benzinga | Apr. 8, 2014 | 09:38AM EST
  50. Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil

    Benzinga | Apr. 8, 2014 | 07:01AM EST
Trading Center